The Cold Open
DSIP is sold as a sleep peptide. The name says so. "Delta Sleep-Inducing Peptide" is right there on the vial. Here's the awkward part: after nearly five decades of research, nobody has identified its receptor, its gene, or its precursor protein. A major 2006 review literally called it a "still unresolved riddle." This month: what DSIP actually does, what the trials actually showed, and why the headline name is doing more work than the data.
Peptide of the Month: DSIP
What it is. DSIP is a nine-amino-acid peptide first reported in 1977 by Swiss researchers who isolated it from the brains of sleeping rabbits. The idea was that animals in deep sleep produced a substance that could transfer sleep to others. They went looking, and found DSIP. That origin story is why it got the name. It's also why the name is misleading: "found in sleeping brains" is not the same as "reliably induces sleep."
What it's supposedly for. Deeper sleep, easier sleep onset, chronic pain relief, stress adaptation, and generalized anti-aging. Modern wellness clinics sell it as a subcutaneous injection, usually taken before bed.
The evidence as of today. Five small human trials, mostly from the 1980s. A 1981 study reported a "normalizing influence" on disturbed sleep, but with a quirk: slight arousal in the first hour after injection, sleep effects only in the second. A 1984 open-label trial in seven insomnia patients reported six of seven improved, with no placebo control. A 1987 double-blind trial in 14 patients reported better sleep. Then came the 1992 double-blind study in 16 chronic insomniacs. The authors found the objective sleep changes were weak, possibly driven by placebo-group variation, and concluded DSIP was "not likely to be of major therapeutic benefit" for insomnia. After that paper, mainstream clinical research on DSIP largely stopped.
One thing to know: no receptor. Most peptides work by binding a specific receptor. DSIP doesn't have a confirmed one. It may modulate opioid or stress-hormone pathways indirectly. "May modulate" after 48 years is not a robust mechanism.
A peptide named for inducing sleep, studied for inducing sleep, and found not to reliably induce sleep.
The catch. Not FDA-approved. The historical trials used IV dosing, but every US vendor sells it as lyophilized powder for SC injection, a route never formally validated in peer-reviewed sleep trials. Clinic protocols are anecdotal extrapolations from half-described 1980s abstracts.
Myth Check: "DSIP is proven to improve sleep"
The marketing leans on the name. Of course DSIP improves sleep. It's in the word.
Here's the reality. The one rigorous double-blind modern trial concluded the opposite. Mainstream sleep medicine has not picked DSIP back up in the 33 years since. It is not in any clinical guideline for insomnia anywhere in the world. Compare that with melatonin, benzodiazepines, or even trazodone off-label, which all have clear, modern, replicated evidence. DSIP has a compelling name, a handful of small studies of mixed quality, and a 1992 paper that effectively closed the file.
The rule: When a peptide's best evidence is older than your driver's license and the most recent rigorous trial said it doesn't work, the name on the vial is marketing, not evidence.
Not medical advice. Most peptides discussed in this newsletter are investigational or research chemicals. Talk to a clinician before starting anything.